FDA Accepts Galderma’s BLA Resubmission for RelabotulinumtoxinA
The agency has accepted the resubmission seeking approval of the neuromodulator for the temporary improvement of moderate-to-severe glabellar lines and crow’s feet in adults.
The agency has accepted the resubmission seeking approval of the neuromodulator for the temporary improvement of moderate-to-severe glabellar lines and crow’s feet in adults.
New sizes for the Mia and Preserve systems expand the company’s minimally invasive breast offerings. The company also presented new clinical data on breast tissue preservation to more than 1,000 plastic surgeons.